- |||||||||| Stivarga (regorafenib) / Bayer
Review, Journal: An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. (Pubmed Central) - Aug 26, 2017 Regorafenib is an oral multi-kinase inhibitor approved as a third-line therapy for advanced GIST and though its efficacy is limited in comparison to imatinib, it has activity across the various driver mutation categories in GIST even in the setting of imatinib resistance. Herein, we describe a case of central retinal vein occlusion (CRVO) secondary to regorafenib and review regorafenib's efficacy and toxicity profile.
- |||||||||| doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Trial primary completion date, Surgery: GOG study : Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery (clinicaltrials.gov) - Aug 24, 2017 P3, N=216, Active, not recruiting, Active, not recruiting --> Suspended Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Jun 2018
- |||||||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Trabectedin Maintenance Post 1st-line in STS (clinicaltrials.gov) - Aug 24, 2017 P3, N=90, Recruiting, Not yet recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019
- |||||||||| imatinib / Generic mfg.
Trial primary completion date: Basket 1: Imatinib in Patients With Desmoid Tumor and Chondrosarcoma (clinicaltrials.gov) - Aug 23, 2017 P2, N=35, Active, not recruiting, Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019 Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, pomalidomide / Generic mfg.
Journal: Kaposi sarcoma herpesvirus-associated disorders and related diseases. (Pubmed Central) - Aug 23, 2017 KSHV is the etiological agents of all forms of Kaposi sarcoma and several other diseases. Strategies employing immunomodulatory agents, cytokine inhibition, and targeting of KSHV-infected cells are areas of active research.
- |||||||||| Phase classification, Trial initiation date: ETOILE: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=250, Not yet recruiting, Strategies employing immunomodulatory agents, cytokine inhibition, and targeting of KSHV-infected cells are areas of active research. Phase classification: P3 --> P=N/A | Initiation date: Nov 2016 --> Oct 2017
- |||||||||| Enrollment closed, Trial initiation date: EPISObs: An Observational Study on Epithelioid Sarcoma (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=100, Active, not recruiting, Phase classification: P3 --> P=N/A | Initiation date: Nov 2016 --> Oct 2017 Not yet recruiting --> Active, not recruiting | Initiation date: May 2017 --> Aug 2017
- |||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial suspension, Myeloid-derived suppressor cells: Dendritic Cell Vaccine for Children and Adults With Sarcoma (clinicaltrials.gov) - Aug 22, 2017 P1, N=56, Suspended, We are currently enrolling patients in a multi-institutional registry to assess the utility of HD-IORT in high risk bladder cancer. Recruiting --> Suspended
- |||||||||| Votrient (pazopanib) / Novartis, Opdivo (nivolumab) / BMS
Enrollment change, Trial withdrawal, Trial primary completion date, Metastases: Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas (clinicaltrials.gov) - Aug 22, 2017 P2, N=0, Withdrawn, Initiation date: Dec 2016 --> Nov 2017 | Trial primary completion date: Dec 2019 --> Nov 2020 N=79 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2020 --> Aug 2017
- |||||||||| ID-LV305 / Merck (MSD)
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 (clinicaltrials.gov) - Aug 21, 2017 P1, N=47, Active, not recruiting, N=79 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2020 --> Aug 2017 Recruiting --> Active, not recruiting | N=59 --> 47 | Trial primary completion date: Dec 2018 --> Dec 2017
- |||||||||| Review, Journal: Uterine Adenosarcoma: a Review. (Pubmed Central) - Aug 19, 2017
The PIK3/AKT/PTEN pathway is mutated in ∼70 % of adenosarcomas, and this may represent a possible therapeutic target. This article reviews the current state of knowledge concerning uterine adenosarcoma and discusses the management of this rare tumor.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Combination therapy, PD(L)-1 Biomarker, IO biomarker: NRG-BN002: Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov) - Aug 18, 2017 P1, N=42, Active, not recruiting, N=64 --> 90 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Nov 2017 | Recruiting --> Active, not recruiting
- |||||||||| humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial completion, Trial primary completion date: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Aug 17, 2017 P1, N=50, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Nov 2017 | Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2014
- |||||||||| Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
Enrollment open, Enrollment change, Trial primary completion date: Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (clinicaltrials.gov) - Aug 17, 2017 P2, N=64, Recruiting, Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2014 Suspended --> Recruiting | N=90 --> 64 | Trial primary completion date: Jul 2017 --> Jun 2019
- |||||||||| IDC-G305 / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date, Metastases: A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (clinicaltrials.gov) - Aug 17, 2017 P1, N=13, Completed, Suspended --> Recruiting | N=90 --> 64 | Trial primary completion date: Jul 2017 --> Jun 2019 Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Nov 2014 --> Dec 2016
- |||||||||| Enrollment closed, Enrollment change, Metastases: ?-TEA in Advanced Cancer (clinicaltrials.gov) - Aug 10, 2017
P1, N=17, Active, not recruiting, Trial primary completion date: Jul 2017 --> Jul 2018 Recruiting --> Active, not recruiting | N=62 --> 17
|